## Contents

1.	Introduction	1
2.	<ul> <li>The parasite</li> <li>2.1 Habitat of adult worms</li> <li>2.2 Mating, insemination and fertilization</li> <li>2.3 Distribution of developmental stages in female worms</li> <li>2.4 Microfilarial release from female worms</li> <li>2.5 Duration of reproductive life span</li> <li>2.6 Correlation between adult worm loads, microfilarial loads and exposure to infective larvae</li> <li>2.7 Suggestions for further study</li> </ul>	3 4 4 5 5 5 6
3.	<ul> <li>The vectors</li> <li>3.1 The Simulium damnosum complex</li> <li>3.2 The Simulium neavei group</li> <li>3.3 Vector capacity and transmission in West Africa</li> <li>3.4 Vector species in the Americas</li> <li>3.5 Vector capacity and transmission in the Americas</li> <li>3.6 Suggestions for further study</li> </ul>	6 8 11 12 13 15
4.	<ul> <li>The disease</li> <li>4.1 Clinical signs and symptoms</li> <li>4.2 Ocular signs and symptoms</li> <li>4.3 Immune responses and pathogenesis</li> <li>4.4 Clinical and immunological changes following treatment with ivermectin</li> <li>4.5 Suggestions for further study</li> </ul>	15 15 18 20 22 24
5.	<ul> <li>Geographical distribution, epidemiology and public health importance</li> <li>5.1 Introduction</li> <li>5.2 Numbers of cases</li> <li>5.3 Geographical distribution and trends</li> <li>5.4 Epidemiology</li> <li>5.5 Public health importance</li> <li>5.6 Suggestions for further study</li> </ul>	25 25 30 37 38 39
6.	<ul> <li>Social and economic impact</li> <li>6.1 Socioeconomic consequences</li> <li>6.2 Community knowledge, beliefs and attitudes</li> <li>6.3 Socioeconomic benefits of control in the OCP area</li> <li>6.4 Cost-benefit analysis of OCP operations</li> <li>6.5 Socioeconomic consequences in the Americas</li> <li>6.6 Suggestions for further study</li> </ul>	40 40 41 42 44 45
7.	<ul> <li>Diagnosis and surveillance</li> <li>7.1 Clinical diagnosis</li> <li>7.2 The Mazzotti test</li> <li>7.3 Parasitological diagnosis</li> <li>7.4 Use of DNA probes for surveillance</li> <li>7.5 Recent advances in immunodiagnosis for surveillance</li> <li>7.6 Suggestions for further study</li> </ul>	45 46 46 47 48 50

.

8.	Treatment8.1Introduction8.2Ivermectin8.3Suramin8.4Amocarzine8.5Benzimidazoles8.6Diethylcarbamazine8.7Evaluation of the effectiveness of chemotherapeutic agents8.8Suggestions for further study	50 50 52 54 56 56 56 57
9.	<ul> <li>Control: objective, strategies and epidemiological modelling</li> <li>9.1 Objective</li> <li>9.2 Factors affecting control strategies</li> <li>9.3 Strategies</li> <li>9.4 Use of epidemiological models to predict trends in the prevalence of infection</li> </ul>	57 57 58 60 62
	9.5 Suggestions for further study	63
10.	Control through vector control 10.1 Operational aspects and impact of insecticide treatments 10.2 Resistance and its management by the rotation of insecticides 10.3 Impact of larviciding on the aquatic environment 10.4 Environmental management 10.5 Integrated control	63 64 67 68 69 69
11.	<ul> <li>Control through chemotherapy</li> <li>11.1 Introduction</li> <li>11.2 Organizations and groups stimulating and supporting the distribution of ivermectin</li> <li>11.3 Methods of distribution</li> <li>11.4 Identification of priority areas for large-scale ivermectin treatment</li> <li>11.5 Suggestion for further study</li> </ul>	70 70 72 75 78
12.	Monitoring and evaluation of control 12.1 Monitoring large-scale chemotherapy 12.2 Entomological evaluation of the impact of vector control 12.3 Evaluation of control 12.4 Suggestions for further study	78 78 79 80 83
13.	Sustainability of ivermectin distribution programmes 13.1 Introduction 13.2 The parties concerned 13.3 Establishment of sustainable programmes 13.4 Cost-effectiveness	84 84 85 86
14.	Training 14.1 Types of training 14.2 Training materials 14.3 Implications of devolution in the OCP area	87 88 89 89
15.	Conclusions	90
16.	Recommendations	91

Acknowledgements	92
References	93
Annex A clinical classification and grading system for recording the cutaneous changes of onchocerciasis	97

.